Beam Therapeutics 計劃最早於 2026 年底提交 risto-cel 的 BLA 申請

8-K 確認該公司預計最早於 2026 年 12 月針對鐮狀細胞疾病提交美國 BLA 申請，由與 Sixth Street 達成的新 5 億美元非稀釋性信貸額度支持，該額度可將現金流延長至 2029 年年中，並為預期的商業上市提供資金。

關鍵事實

申報時間: 2026年2月24日下午12:05
事件: 申請已送件
方向: 正面
公司: BEAMBeam Therapeutics
資產: risto-cel
來源: SEC 8-K
可信度: 有出處
現金可使用期: 至 2029 年年中
最低提領額: 2 億美元
現金融資額度: 5 億美元

來源摘錄

EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Ca

SEC 8-K